相似文献
1
Diagnostic biomarker of asbestos-related mesothelioma: example of translational research.
Cancer Sci. 2007 Aug;98(8):1147-51. doi: 10.1111/j.1349-7006.2007.00520.x. Epub 2007 May 25.
2
Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Pathol Int. 2006 Nov;56(11):649-54. doi: 10.1111/j.1440-1827.2006.02024.x.
3
Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
Cancer Sci. 2008 Apr;99(4):666-70. doi: 10.1111/j.1349-7006.2008.00731.x. Epub 2008 Feb 24.
4
Blood tests for asbestos-related mesothelioma.
Oncology. 2006;71(1-2):26-31. doi: 10.1159/000100446. Epub 2007 Mar 5.
5
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025. Epub 2008 Feb 20.
6
Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):472-9. doi: 10.5507/bp.2014.015. Epub 2014 Apr 29.
7
Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.
8
Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Lung. 2014 Feb;192(1):197-203. doi: 10.1007/s00408-013-9526-9. Epub 2013 Oct 30.
9
Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial.
J Exp Clin Cancer Res. 2022 Aug 20;41(1):255. doi: 10.1186/s13046-022-02455-6.
10
[microRNAs as biological indicators of environmental and occupational exposure to asbestos].
G Ital Med Lav Ergon. 2011 Oct-Dec;33(4):420-34.
引用本文的文献
1
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
J Med Virol. 2018 Oct;90(10):1669-1673. doi: 10.1002/jmv.25229. Epub 2018 Jun 11.
2
Environmental carcinogenesis - 100th anniversary of creating cancer.
Cancer Sci. 2015 Nov;106(11):1483-5. doi: 10.1111/cas.12798. Epub 2015 Oct 21.
3
Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.
Cancer Sci. 2010 Apr;101(4):969-74. doi: 10.1111/j.1349-7006.2009.01463.x. Epub 2009 Dec 9.
4
Diagnostic tumor marker of asbestos-related mesothelioma.
Environ Health Prev Med. 2008 Mar;13(2):71-4. doi: 10.1007/s12199-007-0014-9. Epub 2008 Feb 28.
5
Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
Cancer Sci. 2008 Apr;99(4):666-70. doi: 10.1111/j.1349-7006.2008.00731.x. Epub 2008 Feb 24.
本文引用的文献
1
Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin.
Cancer Sci. 2007 May;98(5):659-64. doi: 10.1111/j.1349-7006.2007.00438.x.
2
Blood tests for asbestos-related mesothelioma.
Oncology. 2006;71(1-2):26-31. doi: 10.1159/000100446. Epub 2007 Mar 5.
3
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.
Mol Cancer Ther. 2007 Feb;6(2):404-17. doi: 10.1158/1535-7163.MCT-06-0343.
4
MESOMARK: a potential test for malignant pleural mesothelioma.
Clin Chem. 2007 Apr;53(4):666-72. doi: 10.1373/clinchem.2006.079327. Epub 2007 Feb 8.
5
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9. doi: 10.1158/1078-0432.CCR-06-1606.
6
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005574. doi: 10.1002/14651858.CD005574.pub2.
7
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes.
Nat Rev Cancer. 2007 Feb;7(2):147-54. doi: 10.1038/nrc2068.
8
Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Pathol Int. 2006 Nov;56(11):649-54. doi: 10.1111/j.1440-1827.2006.02024.x.
9
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31. doi: 10.1158/1078-0432.CCR-06-0472.
10
Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
Cancer Sci. 2006 Sep;97(9):928-32. doi: 10.1111/j.1349-7006.2006.00246.x. Epub 2006 Jun 7.
Zotero 插件